23andMe: Understanding the genetics of pain to identify new treatments for patients
Using DNA to understand why we react differently to pain.
In May 2017, we decided together with 23andMe, Inc. to conduct a joint study in 20,000 participants from the US in order to better understand genetic influences on pain. This study will be one of the largest of its kind to combine data on genetics and response to pain. The study will ask eligible genotyped customers to provide information about their experience with pain via online surveys. Participants will also be asked to self-administer the Cold Pressor Test to determine pain tolerance. The combined data set of survey answers and genetic information will provide insights into the different individual perceptions of pain, the different pathways that are involved, and how best to manage pain with more targeted treatments.Discover More
KU Leuven: Research collaboration for the development of novel non-opioid drug candidates
TRP ion channels: a novel, innovative and potentially pivotal target for non-opioid pain management
In April 2018, Grünenthal entered into a research collaboration with the Katholieke Universiteit (KU) Leuven's Centre for Drug Design and Discovery (CD3) and the Laboratory of Ion Channel Research (LICR). The partnership builds on lead compounds jointly developed by the CD3 and LICR, as well as on the extensive knowledge of Thomas Voets (LICR) and Joris Vriens (LICR), leading experts in the field of TRP ion channels, who have identified a novel, innovative and potentially pivotal target for non-opioid pain management.
"We are delighted to be part of this collaboration. It is a perfect example of an integrated approach that comprises the capabilities of the academic environment, early drug discovery centres and the pharmaceutical industry to deliver innovative solutions for unmet patient needs", Klaus-Dieter Langner, Chief Scientific Officer Grünenthal explains. "To leverage the latest approaches in pain research, Grünenthal is strongly committed to initiate close collaborations with the scientific community on early stage R&D projects."
The Neurobiology of the Placebo Effect – The 1st PainSolve Webinar
We are delighted to have had Prof. Ulrike Bingel (University Hospital Essen, Germany) host our inaugural PainSolve webinar on the 12th December 2018, titled, ‘Psychological and Neurobiological Mechanisms of Placebo and Nocebo Responses.’Discover more
How can the patient experience inform your research?
Chronic pain affects every aspect of patients’ lives. However, the experience of pain is unique to the individual, which is why effective treatment is challenging. This article summarises a patient-centric approach to research that harnesses patient insights to inform the development of new strategies with the potential for greater impact on the lives of those with chronic pain.Discover more
Diagnostic Challenges of Small Fibre Neuropathy
In this article Prof. Páll Karlsson (Aarhus University) highlights the need for a gold standard in the diagnosis of small fibre neuropathy (SFN). Prof. Karlsson focuses on the heterogeneity of SFN as a potential cause of this unmet need, by comparing different characteristics of the disease and those of similar diseases.Discover more
Convergences in PP
Convergences in Pelvi-Perineal Pain is a society that aims to promote knowledge about chronic perineal pain. Over the 2-day programme of this society’s 2018 Congress in Brussels, there were many insightful talks by some of the top researchers and clinicians in this field, an overview of these are discussed in this article.Discover more